EAM
BIIB icon

Empirical Asset Management’s Biogen BIIB Stock Holding History

Empirical Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-875
Closed -$203K – 313
2024
Q2 		$203K Sell
875
-150
-15% -$32.6K 0.08% 306
2024
Q1 		$221K Sell
1,025
-290
-22% -$67.9K 0.11% 250
2023
Q4 		$340K Buy
1,315
+106
+9% +$26K 0.28% 124
2023
Q3 		$311K Hold
1,209
– – 0.27% 118
2023
Q2 		$344K Sell
1,209
-100
-8% -$29.8K 0.3% 107
2023
Q1 		$364K Sell
1,309
-1,542
-54% -$427K 0.35% 100
2022
Q4 		$777K Sell
2,851
-334
-10% -$94.3K 0.82% 35
2022
Q3 		$850K Buy
+3,185
New +$676K 0.93% 28
2022
Q2 		– Sell
-3,183
Closed -$670K – 156
2022
Q1 		$670K Buy
3,183
+2,012
+172% +$438K 0.64% 49
2021
Q4 		$281K Buy
+1,171
New +$301K 0.27% 117

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Empirical Asset Management's BIIB Position: Q3 2024 in Review

Empirical Asset Management sold out of Biogen (BIIB) in Q3 2024, closing a stake of 875 shares — an estimated $203K sold.

Empirical Asset Management first reported a position in BIIB in Q4 2021 and held it in 10 quarters. The position peaked at $850K in Q3 2022. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • Empirical Asset Management reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
  • Empirical Asset Management sold 875 Biogen shares in Q3 2024, an estimated $203K.
  • Empirical Asset Management first reported a position in Biogen in Q4 2021 and held it in 10 quarters.
  • Empirical Asset Management's Biogen position peaked at $850K in Q3 2022.
  • 916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Empirical Asset Management's 13F filing for Q3 2024, filed 11 Oct 2024.